The strategy of combining carbogen breathing and nicotinamide to overcome chronic and acute hypoxia respectively is being evaluated clinically. The effects of both agents individually and in combination on relative perfusion of 400-700 mm3 RIF-I tumours and normal tissues were measured by 'Rb extraction.
It has been generally accepted that hypoxia may be responsible for the failure of clinical radiotherapy, delivered in a fractionated schedule. in some patients. Numerous strategies to overcome this hypoxia have been studied. Relatively recent evidence has supported the hypothesis that it can have a major impact. Overgaard (1992) carried out a meta-analysis of data from a wide range of climical tnrals on over 9000 patients and showed that strategies to overcome hypoxia significantly improved both local control and survival. More direct evidence comes from work correlating direct intratumour oxygen tension measurements with response to radiotherapy. This was first demonstrated in carcinoma of the cervix (Kolstad, 1968) . and interest in the technique has been revived by more recent work in lymph node metastases of the head and neck (Gatenby et al., 1988) with tumour response as an end point, and in advanced primary carcinoma of the cervix (H6ckel et al., 1993) in which both response and survival correlate with oxygenation status.
Current thinking in terms of methods of overcoming hypoxia recognises the need to overcome both chronic hypoxia, occurring in cells located further from a vessel than the maximum distance for diffusion of oxygen, and acute hypoxia, resulting from transient closure of capillaries. Nicotinamide is an effective radiosensitiser of a wide variety of experimental tumours (Horsman et al., 1987 (Horsman et al., . 1989a Kjellen et al.. 1991 : Chaplin et al.. 1991 . thought to act by enhancing tumour perfusion (Horsman et al.. 1989a) , and it has been shown in two tumour systems to act, at least in part, by elimination of transient closure of vessels Horsman et al.. 1990) . It is considered to have relatively low toxicity and is now being assessed clinically in the dose range required to produce the plasma concentrations which are effective radiosensitisers in model systems Rojas et al., 1993a) . The possibility of overcoming chronic hypoxia by breathing carbogen. a mixture of 95% oxygen with 5% carbon dioxide, is also currently being reassessed. Previous clinical investigations of carbogen flagged after a negative study (Rubin et al.. 1979) and in the face of competition from the enormous surge of interest in chemical oxygen-mimetic radiosensitisers in the 1970s. There is now interest in the possibility of combining nicotinamide and carbogen with accelerated fractionation, a strategy designed to increase the efficacy of radiation in tumours with a short potential doubling time (Rojas, 1992) . Much of the evidence supporting these planned European clinical trials is from work on direct measurement of modification of radiocurability of murine tumours by nicotinamide and carbogen (Kjellen et al.. 1991 : Rojas. 1991 Rojas et al.. 1993a,b) . While there is some information for nicotinamide as mentioned above (Horsman et al.. 1 989a: Chaplin et al.. 1990 ) and evidence for increased tumour blood flow was noted in an early report on the effect of carbogen (Kruuv, 1967) , it is tacitly assumed that carbogen acts primarily by increasing the oxygen-carrying capacity of the blood. 
Results
For animals breathing carbogen for 5 min before and during the 1 min exposure to ssRbC1, the effect of increasing the flow rate of carbogen over the animals is shown in Figure 1 . Flow rates of 50-200 ml min-' all increased relative tumour perfusion by between 50% and 70% compared with control (Figure la), increases which are statistically significant (P=0.001 for 50mlmin-' and P<10-3 for 100, 150 and 200 ml min-' compared with conrol) but are not significantly different from one another (P>0.5). At higher flow rates the increase in perfusion was smaller, with an increase of 24% after 250 ml min-' (P = 0.01) and a small increase which was not significant after 300mlmin-' (12%, P=0.24).
In skin and lung significant increases in tissue perfusion (P< 10-3) were observed at all flow rates ( Figure Fugwe I Relative RIF-l tumour and normal tissue perfusion after breathing carbogn for 5 min before and during exposure to 'RbCI, i.e. for a total of 6 min, at a range of flow rates.
Breathing at 150 ml min-' is equivalent to 15 gas exchanges per min. Increases for lung ranged from 36% after 300 mlmin-' to 58°% after 150 mlmin-', while those for skin were rather smaller, ranging from 20% to 34%. The effect -of carbogen breathing on muscle perfusion in these experiments was to reduce relative perfusion to between 80% and 88% of control at 150 to 250 ml min-' (P<l0-3, P=0.016) to a certain extent balancing the effect in skin.
T1he effects on relative perfusion of the spleen, kidney and liver are shown in Figure Ic and Figure 2 . Data are plotted for the total breathing time; 'RbCI was administered 1 min before the end of this. The results for tumour indicate no measurable difference at 2.5min, but significant increases after 4.5, 6 and 9 min (P = 0.001, P<10-3 and P=0.003 respectively) with a peak at 6min with an increase by 94%, suggesting an optimum time of 6min. However, a further experiment (n= 11-13, not illustrated) comparing 6 min with 11 min showed increases of 40% and 61% respectively, with no significant difference between the exposures, so there is no firm indication of a deline in effect between 6 and 11 min, but it is clear that at least 4.5 min breathing is required at 150 ml min-' to achieve an increase. It is again clear from the data in Figure 2 , as with those in Figure 1 , that the inter-animal variation is greater in tumour than in normal tissues. Relative skin perfusion increased by 32% and 31a% after 6 and 9min respectively (P = 0.001) and relative lung perfusion was elevated under all conditions tested, by 32-53% (P<0.002). Muscle perfusion changes were not significant in these experiments, and there were no large changes in perfusion of splen, liver and kidney, although perfusion for all these organs was signifiantly reduced at 2.5 min (P<0.02).
A total breathing time of 6 min at 150 ml min-' was selected for combination with nicotinamide treatment, and relative perfusion was measured 60min after nicotinamide administration. Mice not breathing carbogen also spent 6 min in the appropriate jig. Data are presented in Figure 3 and shdw that in tumour there was no effect of nicotinamide alone, but that carbogen and the combination both produced substantial increases, 42% and 36% rspectively (P<10-), but the effects of both treatments were essentially the same. The data in Figure 3 are pooled for two experiments with rather different sized tumours (see klgend), but a further experiment comparing the effect of carbogen in tumours of both sizes showed that the increase was not dependent on tumour size within this range; increases (±95% CL) were 66 ± 34% for tumours of 400-500 mm3 and 87 ± 16% for those of 550-700mm3 (n = 9-1). There was no major change in relative skin perfusion after any treatment. The substantial carbogen-induced increase in relative perfusion of lung, by 34% in these experiments, was abrogated by the presence of nicotinamide, although nicotinamide alone had no effect. Nicotinamide alone and in conjunction with carbogen produced large increases in relative spleen perfusion, 70% and 46% respectively. However, the effect of carbogen on spleen perfusion and the effects of all three treatments on kidney and liver perfusion were relatively small.
Central tumour temperatures nmasured immediately after animals were restrained are presented in This study shows that carbogen breathing substantially increased the perfusion of the RIF-I tumour, and it is likely that this would contribute to an increase in radiosensitivity. The findings are in agreement with those for the C3HBA mammary carcinoma examined by Kruuv et al. (1967) , also located subcutaneously on the back, in which increased blood flow was deduced indirectly from changes in temperature of the skin overlying the tumour relative to that of the rectum, indicating the core temperature. They contrast TotM bing tim (mm) Flgwe 2 Relative RIF-l tumour and normal tissue perfusion after breathing carbogen at 150 ml min-' for 1.5, 3.5, 5 or 8 min before and during exposure to 'RbCI, i.e. for total times of 2.5, 4.5, 6 or 9 min. Breathing at 150 mlminx is equivalent to 15 gas exchanges per min. (a) Data for tumour (0) and skin (A), (b) data for lung (0) and muscle (A) and (c) data for splen (-) The changes in perfusion observed with carbogen breathing were dependent on gas flow rate and also on breathing time. Flow rates of 50 -200 ml mnn-were almost equally effective, but higher rates had progressively less effect ( Figure  la) suggesting that some sort of compensation mechanism came into play. At a fixed flow rate of 150 ml min'. it was clear that the minimum time for increased perfusion was 4.5 min, but times longer than 11 min were not tested, so no definite conclusion was reached on whether the increase would be eliminated at longer breathing times. Previous studies on the influence of preirradiation carbogen breathing time on radiosensitisation in both KHT (Siemann et al.. 1977 and and SCCVII tumours (Chaplin et al.. 1993 ) have shown that 5-30 min breathing gives maximum effect while with much longer times. 60-120 mmn, radiosensitisation is lost. In the CaNT tumour ) 5 min breathing was the most effective of the range 2-20 min, but all were beneficial, while Suit et al. (1972) found 15 min much more effective than 0.5 mmn in the C3H mammary tumour. The general finding for the time course for radiosensitisation in these tumour systems is that a minimum of 5 min breathing is required for optimum radiosensitisation. which is compatible with that required in the present work in RIF-1 for an increase in perfusion. It therefore seems possible that a perfusion increase may contribute to the radiosensitisation in these tumour models. However, in KHT and SCCVII radiosensitisation is lost after 60 min of breathing (Siemann et al., 1977 : Chaplin et al.. 1993 . while the RIF-l data suggest that perfusion is reduced earlier than this (Figure 2) . A breathing time dependence of the improvement in tumour oxygenation of clinical tumours. as measured by Po2 distribution using microelectrodes, has also been observed (Falk et al., 1992) ; the greatest improvement in oxygenation was seen after 8-12 min breathing and it decreased as breathing continued. This suggests that similar compensation mechanisms may be operating in human tumours.
Relative perfusion changes caused by carbogen breathing in tumour were larger than those observed in any other tissue, but there was considerable variation between tumours. The mean increase (±95% CL) over control caused by 6 min at 150 ml min-' was 65 ± 12% (n = 76). There were small increases in skin perfusion in some experiments (Figures 1  and 2 ) but not all (Figure 3 ). but these increases were invariably much smaller than those in tumour. Owing to its subcutaneous location, tumour would be expected to be There is a rapidly increasing body of data on the radiosensitising properties of nicotinamide and carbogen in model tumour and normal tissue systems. in both single dose and fractionated regimens. From these studies it is becoming apparent that there is considerable variation in the contribution of each treatment to that of the combination, depending on the experimental system used. In some systems the addition of nicotinamide markedly increases the radioresponse with carbogen where the effect of carbogen alone is small, for example in rat spinal cord (Haustermans et al.. 1994) . while in other systems in which the effect of carbogen is much larger the additional increase due to nicotinamide is relatively small. for example in CaNT tumours (Rojas et al.. 1993a) . However, in the SCCVII tumour, in which both agents are fairly effective, the combination is substantially more so (Chaplin et al.. 1993) . but in the KHT tumour. where each agent individually has a greater effect than in SCCVII. the combination is as effective as either agent alone (Siemann et al.. 1994) . In the RIF-1 tumour Donre et al.. (1994) have shown that combined treatment is slightly more effective than nicotinamide alone, but have no data for carbogen alone. Clearly if a fully oxygenated radioresponse is generated by one treatment alone, no additional treatment can provide further benefit. but it is unlikely that this happens in all cases with a single agent. One factor is that nicotinamide treatments may not always have been optimally timed, most investigators having given drug at all doses 60min before irradiation. and it has recently been shown that the peak drug concentration required for maximum radiosensitisation occurs earlier than 60min for drug doses lower than 1000 mg kg-' . Nonetheless. these reported variations in the contribution of each treatment are also compatible with the existence of differences between systems in terms of the ability of their vasculatures to respond to the qualitatively different stimuli provided by carbogen and mncotinamide. If this is also true among human tumours. it provides a further rationale, in addition to the probable existence of both chronic and acute hypoxia. for the superiority of the combination as a therapeutic tool over either agent alone.
In summary. the present data show that in one tumour system carbogen breathing can cause gross increases in relative tumour perfusion. which are likely to improve radioresponse by a mechanism in addition to the generally accepted one of increasing the amount of oxygen carried in the blood. When carbogen breathing is combined with 1000 mg kg-nicotinamide in the RIF-1 tumour at the optimum time for radiosensitisation for this dose. there is no further increase in relative perfusion. Since the combination produces a greater improvement in tumour oxygenation than carbogen alone (Honess et al.. 1995) and greater radiosensitisation than nicotinamide alone (Dorie et al.. 1994) it appears that the mechanisms of improvement in cellular oxygenation by perfusion change by carbogen and nicotinamide differ. A better understanding of these mechanisms is required if these agents are to be employed successfully in the optimisation of radiotherapy in the clinic.
